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Venous thromboembolism (VTE) is responsible for an estimated 25000 deaths per annum in UK hospital practice. It is well
established that many of these deaths could be prevented through the use of appropriate thromboprophylaxis. This issue is of
particular relevance in oncology practice, where the risks of VTE and bleeding are both significantly higher than those observed in
general medical patients. Cancer patients with in-dwelling central venous catheters (CVCs) are at particularly high risk of developing
thrombotic complications. However, the literature has produced conflicting conclusions regarding the efficacy of using routine
primary thromboprophylaxis in these patients. Indeed such is the level of confusion around this topic, that the most recent version of
the American College of Chest Physicians (ACCP) guidelines published in 2004 actually reversed their previous recommendation
(published in 2001). Nevertheless, minidose warfarin continues to be routinely used in many oncology centres in the UK. In this
article, we have performed a systematic review of the published literature regarding the efficacy and the risks, associated with using
thromboprophylaxis (either minidose warfarin or low-dose LMWH) in cancer patients with CVC. On the basis of this evidence, we
conclude that there is no proven role for using such thromboprophylaxis. However, asymptomatic CVC-related venous thrombosis
remains common, and further more highly powered studies of better design are needed in order to define whether specific
subgroups of cancer patients might benefit from receiving thromboprophylaxis.
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In the developed world, venous thromboembolism (VTE) develops
in approximately one in 1000 people each year (Oger, 2000). It
typically presents as a deep vein thrombosis (DVT) of the calf,
which may extend proximally into the veins of the thigh. These
proximal DVT can then give rise to pulmonary embolism (PE)
(Kearon, 2003). Studies have demonstrated that PE are directly
responsible for approximately 10% of all hospital in-patient
deaths, and that they contribute to a further 15% (Geerts et al,
2004). Consequently, over 25000 people are estimated to die from
VTE each year in England alone, and clinical management of acute
VTE costs the UK in excess of d600 million per annum.
It is well recognised that patients with cancer constitute a
particularly high-risk group for both arterial and VTE. Compared
to age and sex-matched controls, the relative risk of VTE is
increased approximately five-fold in patients with cancer (Heit
et al, 2000). Clinically symptomatic DVT have been reported in up
to 15% of patients with cancer (Bick, 1978). However postmortem
studies have demonstrated asymptomatic VTE in as many as 50%
(Ambrus et al, 1975). Multiple mechanisms have been implicated
in explaining the increased incidence of VTE associated with
cancer (Piccioli et al, 1996). Moreover, it is well established that
specific therapeutic interventions (including surgery, chemotherapy
or hormone-based treatment) can further increase the absolute
risk of VTE (Lee, 2005).
Central venous catheters (CVCs) were initially developed by
Broviac et al in 1973, (Broviac et al, 1973) and then subsequently
modified by Hickman et al (1979). They are now widely used in
cancer patients who require intensive chemotherapy and/or stem
cell transplantation. These venous access devices are typically in
the form of either an external catheter (e.g. Hickman or Groshong
line), or an implanted subcutaneous port (e.g. Port-a-Cath).
Although central venous access has revolutionised the clinical
management of cancer patients, there is strong evidence to suggest
that both catheters and ports are associated with a significant
increase in the rate of VTE. The aetiology of CVC-related
thrombosis is likely to be multifactorial in origin. Insertion of
CVCs is associated with traumatic damage to the vessel wall, and
further damage to the endothelial cell lining of the vessel wall may
occur depending upon the final position of the line tip (Eastridge
and Lefor, 1995). In addition, total parenteral nutrition, chemo-
therapy and other drugs infused through the CVC may
exacerbate any local areas of vessel wall damage (Baglin and
Boughton, 1986). Cancer patients with constitutional thrombo-
philias (notably antithrombin deficiency) appear to be at an increased
risk of CVC-related thrombosis, (De Cicco et al, 1995; Tesselaar
et al, 2004) as do those with elevated homocysteine levels, but not
those with the factor V Leiden or prothrombin 20210A gene
mutations (De Cicco et al, 1995; Tesselaar et al, 2004). Ovarian
carcinoma has also been associated with a higher incidence of
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(Tesselaar et al, 2004).
The high rate of VTE associated with CVC in cancer patients has
led to the suggestion that all such patients should receive primary
thromboprophylaxis (in the form of either heparin or warfarin).
Indeed the practise of using thromboprophylaxis for cancer
patients with CVC is now considered routine practise in many
oncology centres across the UK. However, it is well established that
heparin or warfarin use in cancer patients is associated with an
increased risk of bleeding. Consequently the appropriate role of
primary thromboprophylaxis in cancer patients with CVCs
represents a controversial area. In order to establish whether the
available evidence supports current practise, we have performed a
systematic review of the published literature on the efficacy and
the risks associated with using thromboprophylaxis (either
minidose warfarin, or LMWH), in cancer patients with indwelling
CVC.
METHODS
Search strategy
Data for this review was identified by searching the electronic
databases MEDLINE, EMBASE and the Cochrane Library (encom-
passing period January 1966 until November 2005) by two
independent reviewers (MC, JOD). The search terms were
‘catheterisation, central venous’, ‘thrombosis’, ‘oncology’, ‘neo-
plasms’, ‘adult’, ‘anticoagulation therapy’ and ‘haematological’ as
Medical Subject Heading (MeSH) terms and text words. In
addition, the bibliographies of all retrieved articles were also
manually searched for additional relevant articles. Only full papers
published in English between 1980 and 2005 were considered.
Selection criteria
Studies were included in the review if they met the following
criteria:
  Prospective design.
  Study population consisted of adult (more then 14 years) cancer
patients, receiving a CVC – defined as either implantable port or
external catheter.
  Site of catheter insertion defined.
  Some or all of the patients received either heparin or warfarin
thromboprophylaxis at clearly specified dose.
For most articles, selection criteria were apparent. For articles in
which criteria were unclear, the decision for selection was made by
consensus among all the authors.
Data extraction and synthesis
Each study fulfilling the inclusion criteria was reviewed indepen-
dently, by two or more of the authors. All data were extracted
according to a predetermined standard checklist. Disagreements
were resolved by consensus among the authors. The methodologic
quality of each study was critically examined. Clinical outcomes of
interest included incidence of asymptomatic and/or symptomatic
DVT, PE, and overall mortality. In view of the nature of the data
retrieved, quantifiable analysis (met-analysis) was not performed
as part of this study.
RESULTS
Using the specified selection criteria, a total of nine prospective
studies of thromboprophylaxis use in adult cancer patients with
CVC were identified (Table 1) (Bozzetti et al, 1983; Bern et al, 1990;
Monreal et al, 1996; Nightingale et al, 1997; Boraks et al, 1998;
Heaton et al, 2002; Mismetti et al, 2003; Couban et al, 2005; Verso
et al, 2005). Of these studies, one investigated unfractionated
heparin thromboprophylaxis, (Bozzetti et al, 1983) while another
three studied the efficacy of different low molecular weight heparin
preparations (dalteparin, nadroparin and enoxaparin, respectively)
(Monreal et al, 1996; Mismetti et al, 2003; Verso et al, 2005). Use of
minidose warfarin (1mg daily) was studied in six independent
trials, incorporating 1463 patients (Bern et al, 1990; Nightingale
et al, 1997; Boraks et al, 1998; Heaton et al, 2002; Mismetti et al,
2003; Couban et al, 2005).
Incidence of catheter-related thrombosis in cancer patients
In the general population, upper limb DVT is uncommon,
accounting for only approximately 2% of all episodes of DVT
(Marie et al, 1998; Marinella et al, 2000). Long-term indwelling
CVCs appear to be the most common predisposing factor for
upper limb DVT, and have been implicated in between 22 and 72%
Table 1 Description of the prospective studies on thromboprophylaxis for cancer patients with CVC included in this review
Study n Catheter Location Intervention Duration Test Objective VTE Symptomatic VTE
Bozzetti et al (1983)
15
(cohort study)
52 External Subclavian Heparin
2500–3100U daily
6–38 days Venogram Heparin 5/15 (33%)
Control 10/37 (27%)
Heparin 0/15 (0%)
Bern et al (1990)
16
(open randomised study)
121 Port Subclavian Warfarin 1mg daily 90 days Venogram Warfarin 4/42 (10%)
Control 15/40 (38%)
Warfarin 4/42 (10%)
Control 10/40 (25%)
Monreal et al (1996)
17
(open randomised study)
32 Port Subclavian Fragmin 2500IU s.c.
once daily
90 days Venogram Fragmin 1/16 (6%)
Control 8/13 (62%)
Not specified
Nightingale et al (1997)
18
(cohort study)
832 External Sublavian+
jugular+femoral
Warfarin 1mg daily Mean
122 days
Ultrasound7
venogram
Symptomatic only Warfarin 42/949 (4%)
Boraks et al (1998)
19
(cohort study)
108 External Subclavian Warfarin 1mg daily Catheter
duration
Ultrasound7
venogram
Symptomatic only Warfarin 5/108 (5%)
(historical controls)
Heaton et al (2002)
20
(open randomised study)
88 External Subclavian Warfarin 1mg daily 90 days Venogram Warfarin 8/45 (18%)
Control 5/43 (12%)
Not specified
Mismetti et al (2003)
21
(open randomised study)
59 Port Subclavian+
jugular
Nadroparin 2850U
or warfarin 1mg
90 days Venogram Nadroparin 6/21 (29%)
warfarin 4/24 (17%)
Nadroparin 1/21 (5%)
Warfarin 2/24 (8%)
Couban et al (2005)
22
(placebo RCT)
255 Port+
External
Sublavian+
jugular
Warfarin 1mg
or placebo
Catheter
duration
Ultrasound7
venogram
Symptomatic only Warfarin 6/130 (5%)
Placebo 5/125 (4%)
Verso et al (2005)
23
(placebo RCT)
385 External Sublavian+
jugular
Enoxaparin 40mg
or placebo
42 days Venogram Enoxaparin
22/155 (14%)
Placebo
28/155 (18%)
Enoxaparin 2/155 (1%)
Placebo 6/155 (3%)
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et al, 2000). The actual incidence of CVC-related thromboses
reported in cancer patients without thromboprophylaxis varies
widely across different prospective studies (Table 1), and is highly
dependent upon the nature of the study design. In particular,
marked differences relate to whether clinical symptomatic
thrombosis or asymptomatic thrombosis (detected only by
venogram screening), are used as the endpoint of the study. It is
also important to note that the incidence of both symptomatic (1–
8%) and asymptomatic (12–18%) CVC-associated VTE reported
in more recent studies (Mismetti et al, 2003; Couban et al, 2005;
Verso et al, 2005) is also significantly lower than that reported in
the older studies (symptomatic VTE 0–25%; asymptomatic VTE
27–62%) (Bozzetti et al, 1983; Bern et al, 1990; Monreal et al,
1996). This important observation may reflect improvements in
the biocompatibility of the CVCs, and/or improvements in CVC
insertion techniques.
In the prospective studies included in this review, two studies
investigated the risk of venous thrombosis specifically associated
with the use of implantable ports in cancer patients not receiving
thromboprophylaxis. In a prospective follow-up study of 40 cancer
patients with Port-a-Cath subclavian venous catheters who did not
receive any thromboprophylaxis, Bern et al (1990) observed 15
(37.5%) venogram-proven DVT (10 of which were symptomatic)
after 90 days. In this small study, the incidence of thrombosis was
not influenced by either the age of the patient, or by the tumour
type. In a similar study, Monreal et al (1996) identified catheter-
related VTE by venography in 8/13 (62%) cancer patients with
Port-a-Caths in the absence of prophylaxis.
Although several retrospective studies have suggested that the
risk of thrombosis associated with external catheters may be
significantly greater than that observed with implantable ports,
this question has not been addressed in a prospective study. In
terms of the different external catheters used in clinical oncology
practise, the risk of thrombotic complications appears equivalent
for both Hickman and Groshong catheters (Eastridge and Lefor,
1995). However, various other factors have been reported to
influence the incidence of catheter-related thrombosis. For
example, the risk of VTE is significantly higher in cancer patients
who receive triple-lumen compared to double-lumen catheters and
is higher if the catheter is inserted into the left rather than right
subclavian vein (Gould et al, 1993; Craft et al, 1996). Furthermore,
increased incidence of thrombosis has also been observed in
cancer patients where the final catheter tip position has been
placed above the T3 level (Eastridge and Lefor, 1995).
Warfarin thromboprophylaxis in cancer patients with CVC
In view of the high risk of VTE associated with using indwelling
CVC in cancer patients, several reviews have advocated the use
of primary thromboprophylaxis (Klerk et al, 2003). However, it is
well established that the risks of bleeding are significantly higher
in cancer patients (Krauth et al, 1987; Bona et al, 1997). The risk of
major bleeding associated with warfarin therapy can be reduced,
by lowering the target INR. Studies have also shown that even
low-dose warfarin (1mgday
 1) can reduce the rate of thrombin
generation in vivo, (Bauer and Rosenberg, 1987) and significantly
reduce the incidence of DVT following gynaecologic surgery
(Poller et al, 1987). Furthermore, in patients with stage IV breast
cancer, minidose warfarin (adjusted to maintain a target INR 1.3–
1.9), was effective in reducing lower limb DVT (Levine et al, 1994).
On the basis of these observations, several groups have studied the
efficacy of minidose warfarin in cancer patients with CVC.
In an open randomised trial, Bern et al (1990) enrolled 82 cancer
patients who required central venous access (Port-a-Cath sub-
clavian catheters). The patients were then randomised to receive,
or not to receive, warfarin (1mg daily), beginning 3 days before
CVC insertion and continuing for a further 90 days. Prothrombin
times (PT) were monitored regularly throughout the study, and
all patients were subsequently screened by venogram. Of the 42
patients randomised to receive low-dose warfarin therapy, four
(9.5%) patients developed DVT. Conversely, in the control group
of patients not receiving warfarin, 15 out of 40 (37.5%) patients
were found to have developed venogram-proven DVT during the
90-day follow-up period (Po0.001). Despite this marked ther-
apeutic efficacy, the use of low-dose warfarin did not significantly
influence the PT in the majority of the patients studied, and was
not associated with any increase in bleeding.
Minidose warfarin thromboprophylaxis has also been used as
thrombophylaxis to prevent CVC-related thrombosis in patients
with haematological malignancies. Boraks et al (1998) prospec-
tively treated 108 consecutive patients with warfarin 1mgday
 1
commenced on the day of line insertion, and then continued until
the catheter was removed. The prothrombin time was measured
three times per week, and the warfarin dose adjusted to maintain a
target INR o1.6. All patients presenting with clinical signs
suggestive of DVT were investigated with Doppler ultrasound
and/or venogram. Of the patients receiving warfarin prophylaxis,
5% developed clinically symptomatic DVT. The use of minidose
warfarin was not associated with any increased bleeding complica-
tions. However, four patients were noted to have prolonged PT
(420s) that necessitated temporary cessation of their warfarin
therapy. Unfortunately this study did not include a prospective
control cohort. Rather the effect of minidose warfarin was
compared to a historical control group, which fails to satisfy the
selection criteria of this systematic review.
Although the study of Bern et al demonstrated significant
efficacy for minidose warfarin thromboprophylaxis in cancer
patients, more recent studies have failed to reproduce these
findings. Heaton et al (2002) investigated 88 adult patients with
haematological malignancies who required insertion of either a
double lumen Hickman line (n¼78) or double lumen Groshong
catheter (n¼10). A total of 45 patients were randomised to receive
warfarin 1mg daily started on the day of insertion and continued
for a further 90 days or until development of clinical thrombosis.
The INR was monitored on a weekly basis, and if greater than 1.5,
warfarin therapy was temporarily discontinued. In patients with
clinical findings suggestive of either catheter thrombosis (difficulty
in aspirating or injecting into the line), or DVT (arm pain or
swelling), a venogram was performed. There were eight (18%)
cases of confirmed thrombosis in the warfarin-treated group (six
patients with catheter-related thrombosis and two patients with
DVT), as opposed to five (12%) cases in the control group (four
patients with catheter-related thrombosis and one patient with
DVT), leading the authors to conclude that minidose warfarin was
of no therapeutic benefit in preventing CVC-related thrombosis in
patients with haematological malignancies. However, despite the
original study design, it is noteworthy that the patients rando-
mised to the warfarin treatment arm of this study only received
warfarin therapy for a median 41 days. This reduced warfarin
compliance related to a variety of factors including elevated INR,
severe thrombocytopenia, and bleeding complications in one case.
In all, 10 patients treated with warfarin developed prolonged INR
41.5, compared to five patients with no warfarin treatment.
One patient on warfarin and INR 41.5 developed haematuria.
However, this patient had Non-Hodgkin’s lymphoma with tumour
involving his ureters, and was also uraemic.
More recently, a larger randomised, double-blind, placebo-
controlled trial of 255 patients with solid tumours and haemato-
logical malignancies also failed to demonstrate any reduction in
the incidence of symptomatic venous thrombosis for patients
treated with minidose warfarin. Couban et al (2005) randomised
patients to receive either warfarin 1mg daily or placebo. Therapy
was commenced within 72h of CVC insertion, and continued until
the catheter was removed. Ultrasound and venography were only
performed in patients presenting with symptoms suggestive of
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related thrombotic events – five (4%) in the placebo group and six
(4%) in the warfarin arm, respectively. The explanation for the
conflicting conclusions reached by these studies may well relate to
important differences in study design (most notably for example,
Bern et al performed routine screening venography). In addition,
although Bern’s cohort consisted mainly of patients with solid
tumours and lymphomas, the cohort enrolled in the study of
Couban predominantly suffered from haematological malignancies.
LMWH thromboprophylaxis in cancer patients with CVC
Warfarin therapy in cancer patients is associated with a number of
important clinical issues. In particular, fluctuations in INR on
equivalent doses of warfarin are a common problem due to GI
disturbances (vomiting, diarrhoea), cachexia, liver disease and
chemotherapy. In addition, warfarin therapy has a delayed onset
of action, with the full anticoagulant effect not being reached until
2–3 days following commencement of treatment. This delayed
onset of anticoagulant effect, together with the long half-life of
warfarin, means that any surgical interventions must be carefully
planned in cancer patients maintained on warfarin.
In view of the problems associated with use of warfarin in
oncology patients, recent studies have investigated the role of
LMWH thromboprophylaxis in cancer patients with CVC. In an
open, prospective study, Monreal et al (1996) studied 29 cancer
patients who were having Port-a-Caths inserted. In all, 16 patients
were randomised to receive LMWH (Dalteparin 2500IU s.c. once
daily, starting 2h prior to insertion of CVC and continuing for 90
days). Venography was performed after 90 days or sooner if VTE
symptoms were observed. The study was terminated early on the
recommendation of the institutional review committee, as DVT
developed in only 6% of the LMWH treatment group as opposed to
62% of the controls group (P¼0.002). The use of LMWH was not
associated with any increase in bleeding.
More recently, Verso et al reported the first randomised,
double-blind, placebo-controlled study, to assess the efficacy and
safety of enoxaparin thromboprophylaxis (Verso et al, 2005). A
total of 385 cancer patients (including those with haematological
malignancy) were randomised to either enoxaparin (40mg
subcutaneously once daily) or placebo, commencing 2h before
CVC insertion and continued for 6 weeks. All patients underwent
screening venography performed 6 weeks after randomisation,
which demonstrated venous thrombosis in 22 cancer patients
(14%) treated with enoxaparin, compared to 28 cases 18%) treated
with placebo, respectively. The authors concluded that LMWH
thromboprophylaxis with enoxaparin was not associated with
any significant reduction in CVC-associated venous thrombosis. In
keeping with other recently reported studies, it is important to
note that the rate of asymptomatic CVC-associated thrombosis in
the placebo arm of this trial (18%) was significantly lower than that
reported in the older studies (38 and 62%) (Bern et al, 1990;
Monreal et al, 1996) In view of this reduction in absolute baseline
thrombotic complications, future studies will need to be more
highly powered in order to detect subtle differences with
introduction of thromboprophylaxis.
The relative efficacies of LMWH compared to minidose warfarin
have been compared in only one study. Mismetti et al (2003)
randomised 59 cancer patients to receive either minidose warfarin
(1mgday
 1) or LMWH (nadroparin 2850IU OD). Over the course
of a 90-day follow-up, the incidence of venogram-proven upper
extremity DVT was 17% in the warfarin-treated group compared
to 29% for the nadroparin group (P¼0.48). In this study, one
patient with lung cancer receiving nadroparin developed fatal
haemoptysis. On the basis of this small pilot, the authors
concluded that there was no significant difference in efficacy
between minidose warfarin and LMWH thromboprophylaxis.
DISCUSSION
Patients with cancer are at increased risk of VTE, and placement of
CVC further increases this risk. The development of upper
extremity venous thrombosis in a cancer patient with an
indwelling CVC constitutes an important clinical complication.
Pulmonary embolism is generally reported to occur in 10–20% of
patients with upper limb DVT (Horattas et al, 1988; Horne et al,
1995). However, in cancer patients with CVC-related thrombosis,
the risk of PE is significantly higher, occurring in 15% of cases
even if managed using therapeutic anticoagulation (Monreal et al,
1994). Consequently, the development of objectively proven upper
limb venous thrombosis usually necessitates CVC removal.
Subsequently another CVC will need to be inserted at another
site. However, even the temporary loss of central venous access can
result in significant clinical problems. Furthermore, following the
objective diagnosis of any catheter-related DVT, cancer patients
will require full-dose therapeutic anticoagulation (with heparin
and/or warfarin) with the attendant risks of bleeding. Previous
studies have also suggested an increased incidence of CVC sepsis
in patients who develop CVC-related thrombosis (Klerk et al,
2003). In the longer term, post-thrombotic syndrome has been
reported in 30% of cancer patients following upper limb DVT, and
permanent venous damage can result from CVCs (approximately
30% cases), even in cancer patients without a history of CVC-
related thrombosis (Kerr et al, 1990).
In this context, the question of whether primary thrombo-
prophylaxis should be considered for cancer patients with CVC
is clearly of direct clinical importance. However, as we have
demonstrated in this systematic review, there is a paucity of
evidence upon which to base clinical decision making regarding
the role of thromboprophylaxis. In total, only nine prospective
studies investigating the role of thromboprophylaxis in adult
patients with cancer have been identified, and only within the last
year have the first double-blind, randomised-controlled studies
been published. Moreover, six of these nine studies enrolled fewer
than 125 cancer patients in total (Bozzetti et al, 1983; Bern et al,
1990; Monreal et al, 1996; Boraks et al, 1998; Heaton et al, 2002;
Mismetti et al, 2003). In view of the small numbers of patients in
these studies, it is not perhaps surprising that they reached
conflicting conclusions. Furthermore, as a consequence of the lack
of patient numbers, stratification for important confounding
factors (e.g. antithrombin deficiency; elevated homocysteine levels;
side of CVC placement) has not been possible. In addition, the
patient cohorts enrolled in the different studies demonstrate
marked differences. For example, they include a wide variety of
different tumour types and stages. Moreover, in only some of the
studies were patients with haematological malignancies included,
together with patients with solid tumours. Clearly, larger
randomised studies are required in order to establish both the
efficacy and the safety of thromboprophylaxis in cancer patients
with CVCs.
The problem of small cohort size, and discrepant populations of
patients, makes it difficult to perform any meaningful comparisons
between studies in the form of conventional meta-analysis, or even
systematic review. This is compounded by the fact there are critical
differences in study design. For example, the wide range in the
incidence of thrombotic events reported is highly influenced by
whether the end point of the study was defined as symptomatic or
asymptomatic thrombosis. In addition, some of the studies failed
to make any distinction between DVT, and thrombosis restricted
to the lumen of the catheter. Finally, interpretation of the data is
further complicated by the fact that a significant minority of
patients enrolled in these studies were unable to complete their
assigned period of thromboprophylaxis. For example, in the study
of Heaton et al (2002), 38% of lines had to be removed before 90
days in patients receiving warfarin due to line infection, and other
causes besides thrombosis.
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clusions can be drawn from this systematic review of the literature.
Firstly, as previously discussed, the rate of CVC-related venous
thrombosis is significantly lower in recent compared to older
studies. In particular, symptomatic upper extremity DVT is now
relatively unusual, occurring in only approximately 5% of cancer
patients. In contrast, asymptomatic VTE is still detectable in
around 20% cases. The clinical significance of such asymptomatic
thrombi in patients with cancer remains unclear, as little is known
regarding the natural history of CVC-related DVT. Further studies
addressing this issue would be of clinical value.
Secondly, on the basis of the available data, it is not possible to
recommend using routine thromboprophylaxis for all cancer
patients receiving CVCs. In particular, it is important to note that
the only two placebo-controlled trials performed to date failed to
demonstrate any beneficial effect for either warfarin or LMWH
(enoxaparin) thromboprophylaxis (Couban et al, 2005; Verso et al,
2005). However, it remains unclear how therapeutic efficacy and
safety might vary over a range of different warfarin or LMWH
doses. For example, dose of LMWH has been shown to be of
critical importance in determining efficacy in cancer patients
undergoing abdominal surgery (Carr and Rabinowitz, 2000). In
addition, the future use of LMWH thromboprophylaxis may be
influenced by accumulating recent literature suggesting that use
of LMWH in cancer patients is associated with improved
survival (Altinbas et al, 2004; Kakkar et al, 2004; Klerk et al,
2005; Lee et al, 2005). This survival benefit is not entirely explained
by a reduction in symptomatic VTE, raising the intriguing
possibility that LMWH may also exert a direct effect on tumour
cell biology.
Finally, from the studies included in this review, it is clear that
thromboprophylaxis with either warfarin or LMWH is generally
well tolerated in cancer patients with indwelling CVC. Indeed
thromboprophylaxis appears to be safe, even in patients with
haematological malignancies who often have concurrent severe
thrombocytopenia (Boraks et al, 1998; Cortelezzi et al, 2005).
However, it is important to recognise that minidose warfarin
(1mgday
 1) can have a significant effect on the prothrombin time
in cancer patients (Heaton et al, 2002; Masci et al, 2003; Mismetti
et al, 2003; Magagnoli et al, 2005). The aetiology of this increased
prothrombin time is multifactorial, and includes anorexia and
liver metastases (Magagnoli et al, 2005). In addition, it is well
recognised that warfarin can interact with other medications,
leading to significant increases in INR levels. In particular, several
studies have demonstrated an adverse reaction between warfarin
and fluorouracil (FU) (Masci et al, 2003; Magagnoli et al, 2005).
Masci et al (2003) observed significant elevation of the INR in 33%
of patients receiving the combination of minidose warfarin and
FU. Similarly, Magagnoli et al (2005) demonstrated that con-
comitant use of minidose warfarin and the FOLFOX regimen (FU,
folinic acid and oxaliplatin) resulted in INR elevation in 40%
patients (range 1.5–9.4; median 2.9). Consequently, it is evident
that minidose warfarin can significantly prolong the prothrombin
time, at least in selected subgroups of cancer patients. On this
basis, it would appear prudent that all cancer patients treated with
minidose warfarin should have routine prothrombin time (INR)
monitoring, and have their dose of warfarin titrated to maintain an
INR p1.5. To date there is no evidence to suggest that anti-Xa
monitoring is indicated for cancer patients receiving prophylactic
dose LMWH thromboprophylaxis.
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